If you have food allergies, you know the dread: You'll be at a gathering and no one can tell you for sure if there are peanuts or eggs in any of the food. So you take a risk or you don't eat. Now, a ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
A medication used to treat asthma can now be used to help people with food allergies avoid severe reactions, the U.S. Food and Drug Administration said Friday. Xolair, the brand name for the drug ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new positive data from Stage 2 and Stage 3 of the National Institutes ...
Xolair is a branded injectable medication used to treat allergic asthma, chronic hives, and rhinosinusitis. It’s recently been approved to manage food allergies, reducing the risk of serious reactions ...
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...
Please provide your email address to receive an email when new articles are posted on . Data came from the FDA Adverse Event Reporting System from 2004 to 2024. Omalizumab had significant associations ...
Blue Cross Blue Shield is changing how some asthma injections are given, sparking concerns from doctors. Blue Cross Blue Shield (BCBS), under its parent company Health Care Service Corporation, is ...
SAN DIEGO -- Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, ...
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. A medication used to treat asthma can now be ...
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results